Literature DB >> 8591724

Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.

J E Sharer1, L A Shipley, M R Vandenbranden, S N Binkley, S A Wrighton.   

Abstract

The metabolism of probe substrates of phase I and phase II enzymes in vitro were compared in hepatic subcellular fractions from humans, cynomolgus monkeys, rhesus monkeys, and beagle dogs. These studies were undertaken to compare the suitability of these species as models of metabolism in drug development. Eight cytochrome P450-dependent activities were measured in microsomal incubations: ethoxyresorufin O-deethylase, coumarin 7-hydroxylase, tolbutamide 4-hydroxylase, S-mephenytoin 4'-hydroxylase, bufuralol 1'-hydroxylase, N-nitrosodimethylamine N-demethylase, midazolam 1'-hydroxylase, and erythromycin N-demethylase. Seven phase II activities were determined in the appropriate subcellular fractions:acetaminophen UDP-glucurono-syltransferase, acetaminophen sulfotransferase, 17 alpha-ethinylestradiol UDP-glucuronosyltransferase, 17 alpha-ethinylestradiol sulfotransferase, 6-mercaptopurine methylase, dichloronitrobenzene (DCNB) glutathione S-transferase, and isoniazid N-acetylase. Hepatic subcellular fractions from cynomolgus and rhesus monkeys showed significantly higher activities than those from humans for ethoxyresorufin O-deethylase, bufuralol 1'-hydroxylase, midazolam 1'-hydroxylase, erythromycin N-demethylase, acetaminophen UDP-glucuronosyltransferase, acetaminophen sulfotransferase, and tolbutamide 4-hydroxylase. Cynomolgus monkey had higher activity than humans and rhesus monkeys for S-mephenytoin 4'-hydroxylase erythromycin N-demethylase. Rhesus monkey and human cytosol displayed an apparent genetic polymorphism in the N-acetylation of isoniazid, whereas cynomolgus monkey cytosol did not. All other monkey activities were not significantly different than human. Dog subcellular fractions showed higher activity than humans for midazolam 1'-hydroxylase, erythromycin N-demethylase, acetaminophen UDP-glucuronosyltransferase, acetaminophen sulfotransferase, 17 alpha-ethinylestradiol sulfotransferase, and DCNB glutathione S-transferase. Furthermore, dog samples had significantly lower activity for coumarin 7-hydroxylase and 6-mercaptopurine methylase, and no detectable activity for tolbutamide 4-hydroxylase or isoniazid N-acetylase. All other activities were not significantly different from human. These results reveal minor differences between the cynomolgus and rhesus monkey in drug metabolism capacities in vitro, but both species are generally more metabolically active than humans in both phase I and phase II metabolism, whereas dogs had more diverse deviations from humans.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591724

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  17 in total

Review 1.  Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1.

Authors:  A D Kashuba; J R Dyer; L M Kramer; R H Raasch; J J Eron; M S Cohen
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Cloning and characterization of a simian UDP-glucuronosyltransferase enzyme UGT2B20, a novel C19 steroid-conjugating protein.

Authors:  O Barbier; A Bélanger; D W Hum
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

Review 3.  Use of in vivo animal models to assess pharmacokinetic drug-drug interactions.

Authors:  Cuyue Tang; Thomayant Prueksaritanont
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

4.  Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney.

Authors:  Harunobu Tahara; Masayuki Shono; Hiroyuki Kusuhara; Hajime Kinoshita; Eiichi Fuse; Akira Takadate; Masaki Otagiri; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

5.  Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes.

Authors:  Y Li; N Y Li; E M Sellers
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

6.  Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys.

Authors:  Shotaro Uehara; Norie Murayama; Yasuharu Nakanishi; Darryl C Zeldin; Hiroshi Yamazaki; Yasuhiro Uno
Journal:  J Pharmacol Exp Ther       Date:  2011-08-17       Impact factor: 4.030

7.  Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques.

Authors:  Koen K A Van Rompay; Laurie L Brignolo; Dennis J Meyer; Christopher Jerome; Ross Tarara; Abigail Spinner; Marta Hamilton; Linda L Hirst; David R Bennett; Don R Canfield; Trish G Dearman; Wilhelm Von Morgenland; Phil C Allen; Celia Valverde; Alesha B Castillo; R Bruce Martin; Valerie F Samii; Ray Bendele; John Desjardins; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Comparison of oral absorption and bioavailablity of drugs between monkey and human.

Authors:  Win L Chiou; Paul W Buehler
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

9.  Metabolism of propafenone and verapamil by cryopreserved human, rat, mouse and dog hepatocytes: comparison with metabolism in vivo.

Authors:  B Reder-Hilz; M Ullrich; M Ringel; N Hewitt; D Utesch; F Oesch; J G Hengstler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-03-04       Impact factor: 3.000

10.  Pharmacokinetics of 2 formulations of buprenorphine in macaques (Macaca mulatta and Macaca fascicularis).

Authors:  Elizabeth A Nunamaker; Lisa C Halliday; David E Moody; Wenfang B Fang; Matthew Lindeblad; Jeffrey D Fortman
Journal:  J Am Assoc Lab Anim Sci       Date:  2013-01       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.